Rising Demand Spurs US Med-Equip Expansion Across Arizona and the Southwest TUCSON, ARIZONA / ACCESS Newswire / May 1, 2025 / ...

SPOKANE, WA / ACCESS Newswire / May 1, 2025 / Singleton Schreiber is proud to welcome former U.S. Attorney Vanessa Waldref and former Assistant U.S. Attorney Dan Fruchter as partners in the firm's ...

Licensable platform intended to facilitate industry compliance with President Trump's recent Executive Order to expand access to medicines through OTC approvals under his Make America Healthy Again ...

BETHANY, MISSOURI / ACCESS Newswire / May 1, 2025 / Emergency Care Partners (ECP) and its Missouri-based partner physician group, Missouri Physician Partners (MPP), have announced an expansion to ...

Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial ...

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces that the first patient has been enrolled in the Phase 1 clinical trial of its drug candidate 177Lu ...

Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) ...

Key appointment to support company in scaling biorepository and stability storage operationsRochdale, UK, 28 April 2025: ...

SIOUX FALLS, SD / ACCESS Newswire / May 1, 2025 / Teen mental health has reached a crisis point in the United States. According to the CDC, nearly 1 in 3 high school girls reported seriously ...

Cash Burn of $4.0 million in Q1 remains in line with projected quarterly rangeCash and investments on hand are sufficient to fund operations beyond the anticipated FDA decision of VenoValve and the ...

BRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative ...

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic ...